Steven Cohen Relmada Therapeutics, Inc. Call Options Transaction History

Point72 Asset Management, L.P.

1 transactions

Quarter	Operation	Price Per call	calls change	calls Held	SEC Form
Q3 2022 Nov 14, 2022	BUY	$18.3 - $37.02 $1.28 Million - $2.59 Million	70,000 New	70,000 $2.59 Million

12.3M

229K

138K

Ticker RLMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 28,608,500
Market Cap $10.9M
Description
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that ...

Get notified when there are updates to the investment portfolio of Point72 Asset Management, L.P., based on Form 13F filings with the SEC.

Stay updated on Point72 Asset Management, L.P. and Steven Cohen with notifications on news.